Primjena inhibitora kinaza u liječenju bolesnika s uznapredovalim rakom štitnjače by Matea Pešorda et al.
Acta Clin Croat (Suppl. 1) 2020; 59:73-80 Review
doi: 10.20471/acc.2020.59.s1.09
Acta Clin Croat, Vol. 59, (Suppl. 1) 2020  73
KinASe inhibitoRS in the tReAtment  
of thyRoid CAnCeR: inStitutionAl expeRienCe
matea pešorda1, Sanja Kusačić Kuna1,3, dražen huić1,3, davorin herceg2,4,  
marija despot1, tatjana Samardžić1, milena Gnjidić2 and borislav belev2,3
1Clinical department of nuclear medicine and Radiation protection,  
Zagreb university hospital Centre, Zagreb, Croatia;  
2Clinical department of oncology, Zagreb university hospital Centre, Zagreb, Croatia;  
3The university of Zagreb School of medicine, Zagreb, Croatia;  
4The university of Zagreb School of dental medicine, Zagreb, Croatia
SummARy – Although most patients with thyroid cancer have a favorable clinical course, some 
patients develop a more aggressive type of cancer and exhibit more rapid disease progression with 
worse prognosis. Those patients usually exhibit mutations of proteins such as tyrosine kinase enzymes 
that play a significant role in regulation of tumor proliferation and spreading. development of tar-
geted therapies is based on the inhibition of mutated kinases which are involved in the mApK signal-
ing pathway. The aim of this study was to present the initial results of clinical experience with kinase 
inhibitors in patients with metastatic differentiated thyroid cancer (dtC), poorly differentiated thy-
roid cancer (pdtC), and medullary thyroid cancer (mtC) who exhibited rapid disease progression. 
A total of 17 adult patients (11 women, mean age 53.3 years) managed for progressive, metastatic 
disease were included in the study. twelve patients with dtC and pdtC were previously tested for 
bRAf mutations, of whom nine that had tumor tissue negative for the bRAf V600e mutation re-
ceived sorafenib, while three patients with tumors harboring the bRAf V600e mutation were treated 
with vemurafenib. patients with mtC were treated with sunitinib, vandetanib, and sorafenib. two 
patients with tumors harboring the bRAf mutation treated with vemurafenib showed restoration of 
radioiodine uptake. most of patients showed significant improvement in disease status but of limited 
duration until disease progression. Although there was an improvement in progression-free survival, 
future research has to achieve a greater and longer-lasting response, probably by utilizing combined 
targeted therapy.
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Introduction
patients with differentiated thyroid cancer (dtC) 
have a very good prognosis, with a 10 year-survival rate 
of more than 90%,1,2 but that drops to only 10% in case 
of radioiodine refractory disease.3 numerous patients 
with metastatic dtC have an indolent disease course 
and do not require systemic therapy. however, some 
patients have a more aggressive type of dtC with ra-
dioiodine-refractory progressive disease and a have 
worse prognosis.4 Those patients usually exhibit muta-
tions in cell-signaling pathways, and many of the mu-
tated proteins are kinase enzymes that play a signifi-
cant role in the regulation of tumor proliferation, an-
giogenesis, invasion, and tumor spreading. mutations 
of kinases included in the mApK pathway lead to re-
duction of expression of genes included in iodine me-
tabolism and subsequently dedifferentiation of thyroid 
cancer cells.5 development of targeted systemic thera-
pies is based on inhibiting mutated kinases which are 
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involved in the mApK signaling pathway. They can be 
inhibited with small-molecule kinase inhibitors (Ki). 
When starting a treatment with Ki, the choice is be-
tween antiangiogenic multikinase inhibitors (mKi) 
that block multiple kinases with different targets (e.g. 
VeGfRs, Ret, Ret/ptC, eGfR) and more selec-
tive Ki that require prior genetic testing for a specific 
mutation (e.g. for bRAf-directed therapy). There has 
been evidence in pre-clinical and clinical trials that 
mApK pathway inhibitors lead to redifferentiation of 
thyroid cancer cells and restoration of radioiodine up-
take.6-9
poorly differentiated thyroid carcinomas (pdtC) 
represent 6% of all thyroid cancers. They are locally ag-
gressive, metastasize early to the lungs and bones, and 
have a variable radioiodine uptake and poor prognosis. 
many patients require systemic therapy with Ki that is 
similar to therapy for dtC.8,9
medullary thyroid carcinomas (mtC) account for 
3 to 5% of all thyroid cancers. in case of distant metas-
tases, the 10-year survival rate is only 20%.10 The most 
common genetic mutations in mtC are Ret point 
mutations11, but there are no available selective Ret 
kinase inhibitors that are approved for use yet.
Currently available kinase inhibitors have a high risk 
of serious side effects, especially mKis (e.g. renal toxic-
ity, hepatotoxicity, hypertension, myelosuppression, car-
diotoxicity, cutaneous toxicity). based on the above and 
on results of clinical trials in which kinase inhibitors 
only prolonged progression-free survival (pfS) but not 
overall survival (oS),12-15 patients have to be carefully 
selected before starting systemic therapy and need to be 
in active surveillance during treatment.
fdA and emA approved sorafenib and lenvatinib 
for dtC and vandetanib and cabozantinib for mtC, 
and those kinase inhibitors are also approved by the 
Agency for medicinal products and medicinal de-
vices of Croatia. however, at the time the therapy was 
initiated those drugs could not be prescribed at the 
expense of the Croatian health insurance fund but 
were approved for the treatment of tumors other than 
thyroid cancer. Those drugs, as well as other Kis, were 
also available for off-label prescription according to 
literature evidence that they are effective and they will 
be mentioned in this study.
The aim of the study is to present the initial results 
of our clinical experience with kinase inhibitors in pa-
tients who exhibited rapid disease progression.
Patients and methods
total of 17 adult patients (11 women; mean age 
53.3 years at the time of disease detection) managed 
with kinase inhibitors since 2014 at the Clinical de-
partment of nuclear medicine were included in this 
study: 9 with differentiated thyroid cancer (4 with 
papillary and 5 with follicular thyroid cancer, includ-
ing hürthle cell carcinoma), 3 with poorly differenti-
ated thyroid cancer (one of them with both follicular 
and poorly differentiated cancer), and 5 with medul-
lary thyroid cancer. All patients had progressive meta-
static disease, and patients in the group with dtC and 
pdtC had radioiodine refractory disease. twelve pa-
tients with dtC and pdtC were previously tested 
for bRAf mutations. nine patients whose tumor tis-
sue was negative for bRAf V600e mutation (75%) 
received sorafenib therapy under special permission of 
the drug approval committee at the expense of the de-
partment where the patient was being treated. This 
medication is approved for use, but the cost of treat-
ment is not covered by the health insurance fund. 
Three patients with tumors harboring bRAf V600e 
mutation (25%) out of a total of 12 tested patients 
were treated with vemurafenib in order to initiate res-
toration of radioiodine uptake. patients with mtC 
were treated with sunitinib, sorafenib, and vandetanib 
(mainly through off-label use).
All patients were treated with some first-line ki-
nase inhibitors until there were signs of significant dis-
ease progression on morphological imaging (mSCt) 
or until serious side effects occurred. in several pa-
tients, second- or even third-line treatment was intro-
duced when considered clinically appropriate.
our objective was to evaluate the efficacy of tyro-
sine kinase inhibitors and to determine the duration of 
response from beginning of treatment until the signs 
of disease progression, based on radiological assess-
ment. The second goal was to present patients treated 
with vemurafenib and its influence on tumor rediffer-
entiation. finally, we wanted to point out side effects 
of these therapeutic agents. 
Results
from 2014 until the beginning of 2020, a total of 
17 patients were treated with kinase inhibitors at Clin-
ical department of nuclear medicine, Zagreb univer-
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sity hospital Centre. The results are divided into 
groups of patients as described below. 
DTC AND PDTC
twelve patients with dtC and pdtC (8 women, 
mean age 55.5 years; range 43-79) received multiple 
radioiodine therapies after initial surgical resection, 
but in spite of initial treatment and radioiodine thera-
py they developed progressive metastatic disease that 
required systemic treatment with Kis for an average of 
8.8 years after initial cancer diagnosis (range 1 to 22 
years). There were 3 poorly differentiated insular can-
cers between them, while others had papillary and fol-
licular cancer, including 2 hürthle cell carcinoma. 
most of the patients had metastases in the cervical 
lymph nodes and lungs (both 90.9%), mediastinal 
lymph nodes and bones (both 54.5%), but also in the 
brain (36.4%), liver (27.3%), and other sites such as the 
spleen, adrenal gland, kidney, and retina.
nine patients whose tumors were negative for 
bRAf V600e mutation were treated with sorafenib as 
a first-line Ki (daily dose of 800 mg). Among them, 
seven patients (77.8%) had partial therapeutic re-
sponse 3 months after initiating the treatment, but 
only four of them (44.4%) had a prolonged response in 
further follow-up (mean 17.4, range 6-36 months) 
without disease progression. The other 3 patients had 
partial response after 3 months of treatment, as esti-
mated by mSCt, but progressed shortly after the ini-
tial positive response and treatment was discontinued. 
one patient presented with disease progression at the 
first check-up after 3 months since initiating the treat-
ment and died soon after. one patient had just started 
with the treatment while this report was being written 
but had to stop taking the drug after one month due to 
severe side effects (morphological evaluation was not 
yet performed). two patients are still on treatment 
with sorafenib.
Three patients with dtCs harboring bRAf 
V600e mutation were treated with vemurafenib (daily 
dose 960 mg) and two of them showed restoration of 
radioiodine uptake evaluated with i-131 imaging 
(figure 1). one female patient from this group pre-
sented with progression of disease after 2 years of suc-
cessful re-differentiation treatment with vemurafenib, 
which was then replaced by sorafenib as second-line 
treatment, but the patient died shortly after starting 
the treatment (figure 2). The third patient showed 
long-term improvement in lung status on morpho-
logical examination (mSCt) but did not want to per-
form a radioiodine scan.
most patients who were negative for the bRAf 
mutation received sorafenib, which was introduced 
Figure 1. (a) Whole-body iodine-131 scan of patient 
demonstrating no visible uptake at the moment of disease 
progression with loss of previous well radioiodine 
accumulation, and (b) Whole-body scan of the same 
patient six months after vemurafenib therapy 
demonstrating intensive uptake in lung metastases 
(leading to redifferentiation of thyroid cancer cells and 
restoration of radioiodine uptake).
Figure 2. Whole-body iodine-131 scan of a patient with 
progressive disease and multiple metastatic lesions 
previously treated with vemurafenib.
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when the disease progressed and extensive metastases 
accumulated fluorine-18-fluorodeoxiglucose on posi-
tron emission computed tomography (18f-fdG pet/
Ct) but did not accumulate iodine as it was in case of 
patient shown in figure 3.
Some side effects were observed in all patients 
treated with sorafenib and vemurafenib. one of the 
primary adverse events experienced by patients with 
sorafenib was skin rash (8 patients), hand-foot skin re-
action (5 patients), and mild diarrhea in some patients 
as well as weight loss and alopecia. one patient had 
stopped therapy with sorafenib because of extensive 
skin reaction as well as hoarseness. two of nine pa-
tients (22%) required daily dose reduction because of 
the side effects experienced during treatment with 
sorafenib, and in another two (22%) it was necessary to 
withdraw sorafenib temporarily. patients treated with 
vemurafenib developed squamous cell carcinomas of 
the skin (two of them), melanoma (pt1a in one pa-
tient), and keratoacanthomas (two of them). All three 
patients on vemurafenib therapy required occasional 
short-term dose reductions.
Six patients (50%) from the group treated with 
sorafenib or vemurafenib died (five of them in the 
sorafenib group) on average 16.7 months after disease 
progression; range 6-28 months.
MTC
five patients (3 women, mean age 48.2; range 36-
57 years) with progressive metastatic mtC started 
treatment with kinase inhibitors on average 8.2 years 
after cancer diagnosis (range 4 to 11 years). The most 
common metastatic sites in this group of patients were 
cervical lymph nodes (100.0%), mediastinal lymph 
nodes (83.0%), lung and bones (both 66.6%), subcuta-
neous tissue (50.0%), and other sites such as the liver, 
brain, skin, adrenal gland, and kidneys. patients in this 
group received variable treatment options as a first-
line treatment: sunitinib (daily dose 50 mg), vande-
tanib (daily dose 300 mg), and sorafenib (daily dose 
800 mg). patients were given the first drug available at 
that time, and if disease progressed, they were switched 
to the next drug from the group of tyrosine kinase in-
hibitors that was available. most patients received 
sunitinib as first-line therapy because vandetanib was 
only later added to the list of drugs registered and ap-
proved for use on the Croatian market. two patients 
(40%) required second line treatment with sorafenib 
because of disease progression and finally even re-
ceived third-line treatment with vandetanib.
in the group of 4 patients on first-line treatment 
with sunitinib, two of them (50%) experienced partial 
response after 3 months of treatment as evaluated on 
morphological imaging (mSCt). Among them one 
female patient had a stable disease lasting 34 months 
from the introduction of therapy (but with shorter 
breaks in taking the drug due to side effects on the skin 
of the feet); another patient had stable disease for 
about 14 months from the introduction of sunitinib, 
but thereafter developed disease progression without 
significant efficacy of subsequently administered 
sorafenib and vandetanib and died about 2 years after 
disease progression. in one patient, sunitinib therapy 
was omitted during the second cycle of treatment due 
to gastrointestinal bleeding that could be associated 
with a tyrosine kinase inhibitor, but an intestinal polyp 
was subsequently also found. in this group, one patient 
developed fast progression that justified treatment dis-
continuation. most patients had adverse effects during 
treatment that required dose reduction as well as tem-
porary drug withdrawal, most common in the form of 
hand-foot skin reaction (80%), but also nausea, hypo-
calcemia, and low complete blood count (CbC) were 
developed.
Figure 3. Extensive lung metastases accumulated 
18F-FDG on PET/CT but did not accumulate 
iodine-131 in a female patient receiving sorafenib from 
2015 to date, with occasional discontinuation of therapy.
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one patient initially treated with vandetanib expe-
rienced partial response three months after introduc-
tion of treatment, but therapy was discontinued due to 
severe skin infection.
Three patients (60%) from this group died (on av-
erage 21.7 months after disease progression; range 11-
30 months). 
Discussion
Kinase inhibitors represent a novel systemic treat-
ment option for patients with progressive metastatic 
thyroid cancer. Their efficiency was demonstrated both 
in clinical trials and retrospective studies.14-17 Some 
targeted agents (sorafenib, lenvatinib, vandetanib, 
cabozantinib) are approved by the fdA and emA, 
and several other related agents are commonly used as 
off-label drugs for first- and second-line treatments. 
because of potential serious toxicities as well as the 
high cost of these agents, treatment decisions should 
be made by experienced clinicians and patients should 
undergo close monitoring.15
phase iii of a multicenter, randomized, double-
blind clinical trial which studied sorafenib use in ra-
dioiodine refractory dtC (deCiSion) showed im-
proved pfS and response rates as compared with pla-
cebo by 10.8 months and 5.8 months, respectively.14 
Similar improvements were also found in some retro-
spective studies.16-18 in our group of patients with 
dtC and pdtC treated with sorafenib, most patients 
had a partial response with a decrease in tumor mass, 
but unfortunately of limited duration, and none were 
completely cured.
Some patients with dtC develop radioiodine re-
fractory disease and their median survival ranges from 
3 to 6 years.3 Studies have shown that inhibition of the 
highly active mApK pathway leads to redifferentia-
tion of thyroid cancer cells and restoration of radioio-
dine (RAi) uptake.6-9 two our patients treated with 
vemurafenib showed increased RAi uptake on a sub-
sequently performed i-131 whole-body scan about six 
months after starting the treatment. one patient 
showed diffusely increased lung uptake and the other 
one showed increased RAi uptake in the lymph nodes 
of the neck and axilla and in the lungs, bones, and liver. 
both subsequently received radioiodine therapy. one 
of them still has a stable disease as assessed on mor-
phological imaging (six years from the start of treat-
ment with vemurafenib), and the other patient had 
disease progression 2 years after starting the treatment 
and in the end died.
patients with metastatic mtC often have aggres-
sive disease resistant to standard chemotherapy., two 
kinase inhibitors, vandetanib and cabozantinib, were 
recently approved by the fdA and emA for treatment 
of progressive metastatic mtC. in two phase 3 clinical 
trials,12,13 both vandetanib and cabozantinib showed 
longer pfS compared with placebo (30.5 and 11.2 
months, respectively), and both medications showed 
better disease control. Regarding sorafenib and suni-
tinib in this group of patients, their clinical benefit was 
also shown in several phase 2 studies.19-21 most of our 
patients received sunitinib as a first-line therapy which 
resulted in a partial response or stable disease as in oth-
er trials.19,22 According to the literature, sorafenib and 
sunitinib could be considered for use in selected, ad-
vanced patients with mtC who cannot tolerate or who 
are not responsive to vandetanib or who are unable to 
participate in available clinical trials.19,21,23 however, 
vandetanib was used as first-line treatment in one case 
in our group of 5 patients, due to temporary problems 
during pre-registration of the drug because of a change 
of the licensed manufacturer. The other four patients 
with mtC were treated with sunitinib as a first-line Ki 
and two of them (50%) showed partial regression 3 
months after initiation of treatment, as assessed with 
morphological imaging, with the regression being sta-
ble and of longer duration (in one patient lasting one 
year until further progression and another patient hav-
ing stable disease for almost 3 years since the introduc-
tion of therapy). in one case, the disease progressed 3 
months after approval for the use of the drug so suni-
tinib was omitted, and another patient had to stop the 
treatment with sunitinib due to development of possi-
ble side effects in the form of gastrointestinal bleeding 
shortly after introduction of drug. one patient who 
received vandetanib as the first-choice drug showed 
partial regression of tumor changes, but treatment was 
temporarily discontinued due to a skin infection in 
form of papulopustular rash which has also been de-
scribed as a potential side effect in the literature.24,26 
two patients who received vandetanib as the third- or 
second-line therapy showed partial response of short 
duration in further follow-up.
Adverse effects were present in all of our patients 
treated with kinase inhibitors. The most frequent ad-
Matea Pešorda et al. Kinase Inhibitors in the Treatment of Thyroid Cancer
78 Acta Clin Croat, Vol. 59, (Suppl. 1) 2020
verse events in the sorafenib group were rash or des-
quamation, hand-foot skin reaction, diarrhea, and alo-
pecia, which is similar to other studies.14 Some side 
effects required temporary drug withdrawal (31.2%) 
and some required dose reductions (29.4%). This is 
similar to results of clinical trials and retrospective 
studies.17,18,22,23 one patient in our study developed 
gastrointestinal bleeding during sunitinib therapy, 
which is a possible side effect of the therapy. hemor-
rhage has been reported in the literature with certain 
agents, and one of the sunitinib trials reported a 14% 
rate of Gi bleeding, including one grade 5 event.19 
There were no deaths attributable to drug side effects. 
All the patients on vemurafenib developed either 
squamous cell carcinoma of the skin, melanoma, or 
keratoacanthoma during treatment. Studies have dem-
onstrated greater incidence of both benign and malig-
nant skin lesions during treatment with bRAf inhibi-
tors.23
Generally speaking, none of these drugs leads to a 
general cure of the disease, and it is important to weigh 
the risks and benefits of treatment. if the natural 
course of metastatic dtC is a slowly progressing dis-
ease, the risk of adverse events of tKi therapy as well 
as their cost outweigh the potential benefit of those 
drugs. Therefore, the patients must present with at 
least progressive disease within one year before the ini-
tiation of targeted therapy.24,25 furthermore, tKi 
should not be used in patients with only increased cal-
citonin and CeA in the blood and no structural evi-
dence of disease or patients with small tumor masses 
without any evidence of progression on imaging stud-
ies, patients who are generally asymptomatic, or who 
have multiple comorbidities.26 Currently, no precise 
data strongly support the first-line selection of one 
agent over another. individualized selective introduc-
tion of targeted therapies depends on the availability 
of these drugs in the institution that treats thyroid 
cancer, but should be based on the main goal of treat-
ment, potential side effects, and the patient’s re-
sponse.27 
Conclusion
treatments with kinase inhibitors in patients with 
progressive metastatic thyroid cancer are being pre-
scribed at an increasing rate. There has been an im-
provement in progression-free survival with new ki-
nase inhibitors, but a future goal would be to achieve 
greater, longer lasting, and more likely response, prob-
ably by utilizing combined targeted therapy. Accord-
ing to preclinical and clinical trials, inhibition of high-
ly active mApK pathway in patients with dtC could 
induce redifferentiation of tumors and lead to recovery 
of radioiodine uptake in cancer cells. This would lead 
to possible of application of radioiodine therapy that 
could be helpful in improved control of progressive 
metastatic disease. 
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Sažetak
pRimJenA inhibitoRA KinAZA  
u liJeČenJu boleSniKA S uZnApRedoVAlim RAKom ŠtitnJAČe
Matea Pešorda, Sanja Kusačić Kuna, Dražen Huić, Davorin Herceg, Marija Despot,  
Tatjana Samardžić, Milena Gnjidić i Borislav Belev
iako većina bolesnika s karcinomom štitnjače ima povoljan klinički tijek, ipak neki bolesnici pokazuju agresivniji tijek 
bolesti s razvojem uznapredovalih formi tumora i lošijom prognozom. Razlog su vjerojatno mutacije proteina, uglavnom 
enzima tirozin kinaza koji imaju značajnu ulogu u proliferaciji i rastu tumora. Razvoj ciljanih terapija zasnovan je na inhibi-
ranju mutiranih kinaza bRAf, meK, nRAS, c-Kit koje su uključene u signalni put mApK. u radu su predstavljeni preli-
minarni rezultati liječenja inhibitorima kinaza u bolesnika s metastatskim diferenciranim karcinomom štitnjače (dtC), 
slabo diferenciranim karcinomom štitnjače (pdtC) i medularnim karcinomom štitnjače (mtC). u izvješće je uključeno 
ukupno 17 odraslih bolesnika (11 žena, prosječna dob 53,3 godine) liječenih zbog progresivne, metastatske bolesti. dvanaest 
bolesnika s dtC i pdtC prethodno je testirano na bRAf mutacije. devet bolesnika kod kojih je tumorsko tkivo bilo ne-
gativno na mutaciju bRAf V600e primali su sorafenib, dok su tri bolesnika s tumorima koji nose mutaciju bRAf V600e 
liječena vemurafenibom u cilju rediferencijacije tumora, a u dva bolesnika došlo je do ponovne akumulacije radiojoda na 
scintigramu tijela. bolesnici s mtC-om liječeni su sunitinibom, vandetanibom i sorafenibom. u većine bolesnika došlo je do 
pozitivnog terapijskog odgovora uz poboljšanje stanja, ali ograničenog trajanja. buduća istraživanja bi trebala osigurati bolji 
i trajniji terapijski odgovor, vjerojatno primjenom kombinirane ciljane terapije.
Ključne riječi: karcinom štitnjače, inhibitori tirozin kinaza
